Shares in WuXi AppTec, one of those implicated in the Chinese biotech blacklisting legislation, surged following the omission.
Robert BarrieSign up for our daily news round-up! Give your business an edge with our leading industry insights.
Merus’ Bizengri granted FDA accelerated approval to treat NRG1+ cancers
The FDA has granted accelerated approval to Bizengri in the treatment of advanced, unresectable NG1+ lung and pancreatic cancers.
Cell gene therapy: the leading companies in recombinant AAV gene therapy revealed
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms,...
Discover Data Insights powered by our proprietary data
Understand the themes driving your sector, keep up with key innovation areas and track the activities of leading companies
Find out more
Migraine in 68 Markets - Disease Overview, Product Profiles, Patient Flow, ... $10995
Innovation in pharma: recombinant virus-like particles (VLPs)... $250
Migraine in Major Markets, Disease Management, Epidemiology, Pipeline Asses... $10995
M A in the Contract Manufacturing Industry: Implications and Outlook - ... $4995
Pharma Technology Focus
Pharma Technology Focus is our digital magazine, free to read online on all devices. Click the magazine cover to read the latest issue. You can subscribe for free to have each new issue delivered to your inbox.
Subscribe
Sign up for our daily news round-up! Give your business an edge with our leading industry insights.
Give your business an edge with our leading industry insights.
closeI consent to Verdict Media Limited collecting my details provided via this form in accordance with Privacy Policy
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
Thank you for subscribing
View all newsletters from across the GlobalData Media network.
close